Index

Abortion:
  abnormal prenatal test results, information options on, 212
  Canadian laws on, 205–206
  United States laws on, 204–205
  wrongful abortion claims, 116–117

Absolute risk, defined, 361

Accessibility problems:
  abortion laws and, 204–206
  availability of genetic testing, 315–317
  genetic innovation and protection of information and, 430–431
  impact of gene patents on, 335–339
  prenatal genetic testing and screening, 66–167, 193–194
  disability resources, 213
  informed consent barriers, 208–209

Accreditation standards:
  diagnostic genetics, 109–110
  for genetic counseling, 28–29
  laboratories, 309–310
  psychological aspects of genetic counseling and testing and, 60–61

Accuracy of testing, risk assessment and, 343–344

Acetylcholinesterase (AChE):
  open neural tube defect diagnosis, 174–175
  prenatal screening and diagnosis, 165, 169

Achondroplasia, risk assessment for, 347–348

Actuarial fairness, genetic discrimination in health insurance, 161–162

Addiction, “genetic predisposition” theory, 234–236

Adolescents, genetic susceptibility testing in, 279–280

Adoption studies:
  diagnostic genetics and wrongful adoption claims, 126–127
  neurogenetics, 223–225
  Adrenal hyperplasia, risk assessment, null alleles, 348–349

Adult-onset hereditary disorders. See also
  Common chronic adult disease, family history and genetic screening for
    Alzheimer’s disease, 226
    chromosome anomalies, 301–302
    family history in, 92–93
    genetic susceptibility testing, 116–117
    preimplantation genetic diagnosis, ethical issues, 200–201
    psychological aspects of genetic counseling and testing, 61–78
    ambiguous test results, guidelines for, 71–72
    clinical implications of, 74–77
    disclosure of result, posttest phase, 66–67

*Genetic Testing: Care, Consent, and Liability*, by Neil F. Sharpe and Ronald F. Carter
© 2006 John Wiley & Sons, Inc.
Index

Adult-onset hereditary disorders

(Continued)

family reactions to, 72–73
negative test result, absence of mutation, 70–71
positive test result for mutation, 67–70
pretest counseling phase, 63–66
societal and ethical issues, 73–74
testing process, 62–63

societal and ethical issues, 73–74

Adverse selection, health insurance discrimination, 159–160

Aftercare procedures, communication of test results, 379–380

Alleles:

Alzheimer’s disease neurogenetics, 226
carrier screening, Fragile X syndrome, 266
conduct disorder neurogenetics, 234
epilepsy neurogenetics, 229–230
hemoglobinopathies, 262–263
neurogenetics of, 224–225
null alleles, risk assessment, 348–349

α-fetoprotein (AFP):

prenatal screening and diagnosis, 164–165, 169–170
mechanisms of, 179
ONTD screening and metabolism, 170–173
test results, communication of, 366–368

α-fetoprotein in the amniotic fluid (AFAFP):

open neural tube defect diagnosis, 174–175
prenatal screening and diagnosis, 171–173

Alpha-1-antitrypsin (AAT) deficiency, susceptibility testing, 272

Alpha-synuclein, Parkinson’s disease, 227–228

Alport syndrome, linkage analysis, risk assessment, 350–352

Alzheimer’s disease:

clinical presentation, 220–221
neurogenetics of, 225–226

Ambiguous test results, in adult-onset hereditary disorders testing, psychological impact of, 71–72

Ambivalence concerning genetics, research on, 429–431

Americans with Disabilities Act (ADA), genetic discrimination and, 153–154

Aminoacidopathies, biochemical testing, 306–307

Amniocentesis:

communication of results:
cultural factors for Latino patients, 31–32, 35–36
miscommunications concerning, 32–37, 43–44
trust and confidence issues in, 40–42
in multilingual situations, 37–40
prenatal diagnosis applications, 190–192
sampling and laboratory protocols, case studies, 292–294

Amyloid precursor protein (APP), Alzheimer’s disease genetics, 221, 225–226

Analytic decision-making, techniques for, 51–52

Anxiety, psychological aspects of genetic counseling and testing and, 57

APOE ε-2 gene, Parkinson’s disease, 227–228

APOE ε-4 gene:

Alzheimer’s disease, 220–221, 226
susceptibility testing, 235–236

Archived specimens, testing with, 311

Ashkenazi Jewish population, carrier screening in, 263–265

Aspartoacylase enzyme, Canavan disease, 264–265

Association studies:
bipolar disorders, 233
schizophrenia, 232

Australian Law Reform Commission (ALRC), genetic innovation and protection of information, 425–442

Autism:
clinical presentation, 221
neurogenetics, 230–231

Automated gene sequencing, sampling and laboratory protocols, 295–296
Automatic decision-making, techniques for, 51–52
Autosomal dominant inheritance patterns:
   Alzheimer’s disease genetics, 221
   Parkinson’s disease, 227–228
Autosomal-dominant nocturnal frontal epilepsy, neurogenetics, 230
Autosomal recessive inheritance patterns:
   carrier screening:
      Ashkenazi Jewish population, 264–265
deficiency, 266–267
   Parkinson’s disease, 227–228
Availability of testing:
   complexities of, 315–317
   impact of gene patents on, 335–339
Bacteria growth inhibition assay, newborn screening, 250
Bayesian analysis, risk assessment using, 344–345
Behavior modification, genetic testing and use of, 50–52
Benefits of testing:
   adult-onset hereditary disorders testing,
      positive results (presence of mutation), response to, 69–70
   psychological aspects of genetic counseling and testing and potential for, 56–57
   susceptibility testing, 269–270
      in children, 280–281
Benign rolandi epilepsy (BRE), neurogenetics, 229–230
β-globin genes, hemoglobinopathies, 262–263
β-human chorionic gonadotropin:
   placental-derived markers, 178
   trisomy 18 diagnosis, 184
Bilateral breast cancer risk, 392–394
Binary interpretation pattern, of tests results, 364–365
Biochemical genetics testing:
   disease diagnosis, 302–307
   indications for, 296
   limitations of, 312
   prenatal diagnosis and screening, 196
   sampling and laboratory protocols, 295–296
Bipolar disorders:
   clinical presentation, 222
   neurogenetics, 232–233
Blood dot cards, newborn screening systems, 253
Bloom syndrome, carrier screening, 265
Blunter reaction, as coping mechanism, communication of test results and, 368–369
BRCA1 and 2 genes:
   breast conservation and mutations in, 391
   founder mutations, breast cancer risk assessment, 349–350
   hereditary breast cancer syndromes, susceptibility testing, 273–276
   mutation carriers, bilateral breast cancer risk, 393–394
   mutations and genetic testing, 387–388
Myriad Genetics issue and, 336–337
nonhereditary/hereditary cancer origins, 387
   patent issues for, 334–335
   risk assessment and mutations in, 388–391
   recontacting patients, duties regarding, 417
Breast cancer:
   hereditary syndromes, susceptibility testing, 273–276
   case study, 282–283
   risk assessment:
      average population risk, 384–385
      bilateral risk, 392–394
      family history and, 386–391
      founder mutations, 349–350
      hormone replacement therapy and, 394–397
      tamoxifen and prevention of, 391–392
Canada:
   abortion laws in, 205–206
   genetic innovation in, 332–333
   innovation in genetics and protection of information in, 440–442
   newborn screening policies, 246–247
Canavan disease, carrier screening, 264–265
Index

Cancer genetics:
- breast cancer:
  - invasive lobular carcinoma, 394
  - tamoxifen and prevention of, 391–392
- health insurance discrimination, 158–160
- hereditary cancer syndromes,
  - susceptibility testing:
    - breast/ovarian cancer, 273–276
    - colorectal cancer, 276–278
    - familial adenomatous polyposis, 278–279
- referrals for diagnostic testing:
  - obligations concerning, 119
  - primary care physicians’ obligations, 120–122
- risk assessment:
  - average risk, breast and ovarian cancer, 384–385
  - bilateral breast cancer risk, 392–394
  - case studies, 382–383
  - diagnosis vs. prognosis, 385–386
  - family history, 386–391
  - hormone replacement therapy, 394–397
  - overview of research, 383
  - testing techniques, 62–63
  - sampling and laboratory protocols, 296
- web resources, 443

Candidate-gene study, neurogenetics, 225

Carrier screening:
- Ashkenazi Jewish population, common diseases, 263–265
- basic principles, 254–255
- case history, 255–256
- communication of results, 376–378
- current status of, 258
- cystic fibrosis, 258–260
- case study, 359
- deafness, 266–267
- fragile X syndrome, 266
- goals of, 256
- hemoglobinopathies, 261–263
- implementation, 258
- protocol development, 256–258
- risk assessment, 362
- strategies for, 257–258
- target population, 256–257
- technical issues, 257

Cascade carrier screening, strategies for, 258

Causality, legal model for informed consent and, 130–131

Cerebrospinal fluid (CSF), prenatal screening and diagnosis, 169–170

CFTR gene:
- carrier testing, 376–378
- cystic fibrosis carrier screening, 259–260

Children:
- cytogenetic studies, 300–301
- susceptibility testing in, 279–282
- benefits of, 280–281
- decision making principles, 282
- ethical issues, 279–280
- potential harm, 281
- risk-benefit tradeoff, 288–289
- Chip-based screening, sampling and laboratory protocols, 296

Choice, role of, in nondirected counseling, 8–9

Chorionic villus sampling (CVS):
- cystic fibrosis carrier screening, 260–261
- prenatal diagnosis applications, 190–192
- prenatal screening and diagnosis, 169

CHRNA4 gene, epilepsy neurogenetics, 228–230

CHRNB2 gene, epilepsy neurogenetics, 230

Chromosomal anomalies:
- developmental disorders, 297–302
- adult-onset disorders, 301–302
- neonatal and pediatric cytogenetics, 300–301
- prenatal diagnosis, 299–300
- genetic testing indications for, 296
- interpretation of results, 325–326

CLCN2 gene, epilepsy neurogenetics, 229

Clinical diagnosis:
- chronic adult disease, family history and, 98
- communication guidelines for, 44–46
- diagnostic criteria, 45
- molecular genetics and, 46
- patient history, 44–45
- limitations of, 353
- significance of test results in, 312–313

Clinical implications:
- of family history, 88
- psychological aspects of genetic testing and, 74–77
Clinical management:
  duty to recontact, obligations concerning, 411–413
  genetic testing use in, 310–311
  impact of patents on, 333–335
  implementation of test results, 313
Clinical significance, of test results, 360
Clinical validity/utility, informed consent and, 134–135
Clinician obligations:
  genetic disease diagnosis, 108–109
  genetic test ordering and interpretation, 307–308
COLAA gene family, Alport syndrome, risk assessment, 351–352
Colorectal cancer, hereditary syndromes, susceptibility testing, 276–278
Commercialization of human genes, ethical debate over, 330–331
Common chronic adult disease, family history and genetic screening for:
  basic principles, 94
  individual risk assessment strategies, 94–95
  molecular testing, 97–98
  overview, 93–94
  risk assessment guidelines, 95–97
Communication in genetics testing and counseling:
  client cultural and intellectual characteristics, 48
  clinical diagnosis case study, 44–47
  confidence and trust issues, 40–42
  amniocentesis, women’s acceptance of, 41–42
  amniocentesis, women’s refusal of, 40–41
  decision-making considerations and approaches, 50–52
  diagnostic criteria and, 45
  educational tools and facilitators, 48–50
  effectiveness of, guidelines for, 24–27
  ethical issues, 46
  counseling guidelines, 46–49
  fetal diagnosis, cultural factors in, considerations for Latino patients, 31–32
  informed consent and, 136–137
  place and time guidelines, 138–139
  laboratory reports to patient and physician, 321–322
  language skills used for, 366–368
  methods for, 30
  miscommunication and patient dissatisfaction, 42–44
  molecular genetics principles, 46
  multilingualism, translation and second-hand information issues, 37–40
  family and friends as translators, 39–40
  genetic consultation, 37–38
  on-site translators, 37
  post-consultation interview, 38–39
  need to know principle, 27–28
  patient history, 44–45
  physician-patient relationship and, 24–25
  prenatal genetic care, miscommunication and, 32–37
  cultural sensitivity, 35
  genetic consultation, 35–36
  idioms and jargon, 33–34
  nondirectiveness, guidelines for, 34–35
  opportunistic observation, 36–37
  professional disclosure of results, 409–410
  duty to warn family members, 413–414
  recontact in clinical settings, duties regarding, 411–413
  in research settings, 410–411
  professional obligations in, 29
  risk assessment, communication of, 359–363
  setting for, 366
  standards for, 28–29
  terminology, tone, and follow-up guidelines, 30
  of test results, practical steps towards, 365–370
  timing of, 365
Comparative genomic hybridization (CGH):
  evolution of, 321
  preimplantation genetic diagnosis, 190–192
Competency obligations, in diagnostic genetics, 110–111
Complete blood count (CBC), hemoglobinopathy screening, 262–263
Complexity in genetic testing:
- availability issues, 315–317
- legal and ethical issues, 151–152
- neurological disorders, 219–220
- ordering and interpretation protocols, 314–319

Computer-based programs:
- as genetic counseling educational tool, 49–50
- informed consent and use of, 142–143

Concordance studies, neurogenetics, 224–225

Conditional probability(ies), in risk assessment, 344–345

Conduct disorder, neurogenetics, 233–234

Confidence issues, in communication of genetic test results, 40–42

Confidentiality:
- genetic innovation and protection of information and, 430–431
- in genetic testing, 398–400
- prenatal/preimplantation genetic counseling, 217–218
- congenital hypothyroidism, newborn screening, 241–243
- legal aspects of, 246–247

Consent. See Informed consent

Contingent sequential screening, Down syndrome, 183

Continuing education training:
- in diagnostic genetics, 109–110
- web resources, 443–444

Continuum of distress, psychological aspects of genetic counseling and testing and, 76–77

Cordocentesis, prenatal diagnosis applications, 190–192

Cost issues. See also Benefits of testing
- in laboratory selection, 319–320
- newborn screening, 241
- legal aspects of, 248–250
- policy making and, 244–245

Cultural factors:
- client characteristics, 48
- in clinical diagnosis, neurofibromatosis case study, 44–46
- communication of test results and:
  - Latino patients, considerations for, 31–32
  - miscommunication, risk of, 42–44
  - sensitivity to, 35
  - in genetic counseling, 15–16
  - informed consent and, 140–141
  - innovation in gene research, protection of information and, 438–442
  - psychological aspects of genetic testing and, 73–74

Cutoff value:
- newborn screening, 239–240
- prenatal screening and diagnosis, 167–170
- C282Y gene, hereditary hemochromatosis susceptibility testing, 271–272
- communication of results, 375–376
- CYP21A and B genes, null allele risk assessment, 348–349

Cystic fibrosis (CF):
- carrier screening:
  - Ashkenazi Jewish population, 265
  - case study, 255–256
  - communication of results, 376–377
  - current status, 258–260
- newborn screening systems for, 254
- prenatal and preimplantation diagnosis, ethnicity issues, 194
- risk assessment for, 346–347

Cytogenetic testing:
- autism, 230–231
- chromosomal anomalies, development disorders, 297–302
- chromosomal translocation case study, 107–108
- limitations of, 312
- sampling and laboratory protocols, 294–296

Deafness:
- carrier screening, 266–267
- prenatal/preimplantation genetic diagnosis, 201–204

Decision-making:
- in breast cancer risk assessment, 391
- genetic testing and issue of, 50–52
- prenatal/preimplantation diagnosis, pressure for, 213–214
- reproductive decision making:
  - genetic counseling and:
    - current trends in, 14
    - historical perspective, 12–13
prenatal genetic diagnosis:
abortion laws, 204–206
informed consent issues, 207–208
susceptibility testing, in children and adolescents, 282
Dehydroepiandrosterone sulfate (DHEAS), unconjugated estriol (MSuE3), 179
Delegation issues, informed consent and, 140
\textit{delF508} mutation, null allele risk assessment, 348–349
Detection rates (DR):
newborn screening, 239–240
prenatal screening and diagnosis, 164–165, 168–170
of test results, 359–360
Diagnostic genetics testing, 108–110
basic principles, 19–20
breast and ovarian cancer, prognosis \textit{vs.} diagnosis, 385–386
clinician obligations, 108–109
competency and referral obligations, 110–117
prenatal diagnosis, 111–112
wrongful abortion, 116–117
wrongful birth issues, 113–114
wrongful life issues, 115–116
Huntington disease, nonsymptomatic patient, 372–375
nonsymptomatic patient case study, 358
\textit{vs.} prenatal screening, 210–211
primary care physicians, referral role of, 120–122
professional expertise, standards for, 109–110
referral criteria, 117–120
cancer genetics, 119
geneic test centers, 120
prenatal diagnosis, 118–119
susceptibility testing, prediction \textit{vs.}, 287
symptomatic patient case study, 358
\textit{vs.} prenatally screening, 210–211
primary care physicians, referral role of, 120–122
professional expertise, standards for, 109–110
referral criteria, 117–120
cancer genetics, 119
geneic test centers, 120
prenatal diagnosis, 118–119
susceptibility testing, prediction \textit{vs.}, 287
symptomatic patient case study, 358
\textit{vs.} prenatally screening, 210–211
primary care physicians, referral role of, 120–122
professional expertise, standards for, 109–110
referral criteria, 117–120
cancer genetics, 119
geneic test centers, 120
prenatal diagnosis, 118–119
susceptibility testing, prediction \textit{vs.}, 287
symptomatic patient case study, 358
\textit{vs.} prenatally screening, 210–211
primary care physicians, referral role of, 120–122
professional expertise, standards for, 109–110
referral criteria, 117–120
cancer genetics, 119
geneic test centers, 120
prenatal diagnosis, 118–119
susceptibility testing, prediction \textit{vs.}, 287
symptomatic patient case study, 358
\textit{vs.} prenatally screening, 210–211
primary care physicians, referral role of, 120–122
professional expertise, standards for, 109–110
referral criteria, 117–120
cancer genetics, 119
geneic test centers, 120
prenatal diagnosis, 118–119
susceptibility testing, prediction \textit{vs.}, 287
symptomatic patient case study, 358
\textit{vs.} prenatally screening, 210–211
primary care physicians, referral role of, 120–122
professional expertise, standards for, 109–110
referral criteria, 117–120

disease diagnosis, genetic testing, 302–307

Distress. \textit{See Stress}
communication of results as trigger for, 369–370

DNA testing, carrier screening, 257

Dose-dependent risk, Alzheimer’s disease, 226

Down syndrome:
amniocentesis sampling and laboratory protocols, 293–294
integrated first- and second-trimester screening, 182–183
neurogenetics of, 223

Dimeric inhibin-A (DIA):
Down syndrome diagnosis, 176–177
placental-derived markers, 178–179
Direct-to-consumer susceptibility testing:
ethics of, 290–291
innovation in gene research, protection of information and, 435–442

Disability:
prenatal/preimplantation genetic diagnosis, 201–204
ethical limits of, 203–204
social aspects and access to resources, 213
stigmatization of, 202–203

Disclosure of results. \textit{See also Confidentiality}
in adult-onset hereditary disorders testing, posttest counseling guidelines, 66–67
informed consent and, 132–134
delegation issues, 140
place and time guidelines, 138–139
tone and manner of disclosure, 139–140
legal and ethical aspects of, 400–402
prenatal diagnosis:
abnormal results, information transfer, 212
information transfer, 209–211
professional disclosure duties, 409–410
duty to warn family members, 413–414
recontact in clinical settings, duties regarding, 411–413
in research settings, 410–411

Discrimination issues, web resources for, 143

Disease diagnosis, genetic testing, 302–307

Distress. \textit{See Stress}
communication of results as trigger for, 369–370

DNA testing, carrier screening, 257

Dose-dependent risk, Alzheimer’s disease, 226

Down syndrome:
amniocentesis sampling and laboratory protocols, 293–294
integrated first- and second-trimester screening, 182–183
neurogenetics of, 223
Index

Down syndrome (Continued)
  prenatal screening and diagnosis, 175–177
  chromosomal anomalies, 299–300
  contingent sequential screening, 183
  first-trimester screening, 182
  second-trimester screening, 181–182
  triple or quad screen test, 196
Drug risks, duty to warn patients concerning, 423
Duchenne muscular dystrophy, neurogenetics of, 223
Duty of care, in genetic testing and counseling:
  conceptual guidelines for, 83–84
  legal precedents for, 81–84
  overview of, 79–80
  prenatal diagnosis:
    human vs. medical vision of, 214
    information transfer concerning, 209–211
  recontacting patients as continuing duty, 421–422
  standards of, 80–81
Duty to recontact, legal principle of, 416–424
Duty to warn, disclosure of test results and legal principle of, 403–407
Early-onset of disease, Alzheimer’s disease, 221
Echogenic bowel, trisomy 21 diagnosis, 186
Echogenic intracardiac focus (EIF), trisomy 21 diagnosis, 187
Economic issues, genetic discrimination and, 146–148
Educational tools:
  chronic adult disease, family history and, 98–102
  for communication of test results, 366–367
  for genetic counseling, 48–50
  informed consent and, 142–143
  web resources, 145
  newborn screening systems, 253
  for New Genetics, 439–442
  web resources, 356, 449
Emotional response:
  adult-onset hereditary disorders testing:
    negative results (absence of mutation), 70–71
    to positive results (presence of mutation), 67–70
    psychological assessment in pretest phase, 65–66
  prenatal/preimplantation diagnosis, counseling for, 214
Environmental factors:
  neurological disorders, 219–220
  ethical issues, 235–236xc
  Parkinson’s disease, 226–228
Enzyme assays, carrier screening, 257
Enzyme-linked immunosorbent assay (ELISA), newborn screening, 250
Epigenetic mechanisms, neurological disorders, 219–220
Epilepsies:
  classification, 228
  clinical presentation, 222
  genetics of, 228–230
Equivocal results, interpretation of, 326
EST patenting controversy, 335
Ethics of genetics testing and counseling, See also Legal aspects of genetics testing
  basic principles, 1, 11–12
  confidentiality issues, 398–400
  disclosure of test results, 400–402
  duty to warn principle, 403–407
  professional disclosure duties, 409–410
  duty to warn family members, 413–414
  recontact in clinical settings, duties regarding, 411–413
  in research settings, 410–411
  risks and harm, issues of, 407–408
  web resources on, 408
Duty of care standard and, 79–84
Family history:
  pedigree analysis, 89
  prenatal genetic diagnosis, 90–91
  genetic discrimination issues, 146–151
  insurance coverage, 156–162
  genomic patent policies, 328–329
clinical genetic testing services, 335–336
human gene patent debate, 329–331
impact on research and clinical environment, 333–335
innovation and, 331–333
Myriad Genetics case study, 336–337
overview, 328–329
human gene patent debate, 329–331
innovation in gene research, protection of information and:
actual vs. potential applications, 433–434
current regulatory framework, 426–427
human interest in, 429
policy action plan for, 434–442
public ambivalence concerning, 429–431
rapid changes in, 431–432
neurogenetics testing, 234–236
neurological disorders, limited value of genetic testing, 222
predictive complexity and, 151–152
prenatal genetic diagnosis:
access issues, 166–167
confidentiality, 217–218
disability screening, 201–204
health care provider obligations, 197–198
informed consent issues, 206–214
public policy issues, 198
stigmatization of disability, 202–203
susceptibility testing, 200–201
wrongful adoption claims, 126–127
psychological aspects of genetic testing, 73–74
recontacting patients, issues involving, 415–424
release of test results, research testing, 310–311
susceptibility testing, 287
adult-onset disorders, 282–285
in children, 280–281
direct to consumer testing, 290–291
web resources, 444
Ethnic background:
carrier screening protocols, 256–257
Ashkenazi Jewish population, 263–265
cystic fibrosis, 259–260
deafness, 267
hemoglobinopathies, 261–263
family history taking:
pedigree analysis and, 99–100
prenatal/neonatal testing and, 92
target populations in, 256–257
Ethnicity-based data:
genetic test results and, 360–361
prenatal and preimplantation diagnosis, 195
Evidence-based access, prenatal and preimplantation diagnosis, 193–194
Evolutionary theory, innovation in gene research and, 438–442
Fabry disease, newborn screening systems for, 254
Facilitators, for genetic counseling, 48–50
False-positive rate (FPR):
newborn screening, 239–240
prenatal screening and diagnosis, 164–165, 168–170
Familial adenomatous polyposis (FAP), susceptibility testing, 278–279
Familial dysautonomia, carrier screening, 265
Family dynamics:
adult-onset hereditary disorders testing:
impact on, 72–73
negative results (absence of mutation), 71
positive results (presence of mutation), response to, 69–70
in pretest phase, 65–66
communication of test results and, 368–369
interpretation of test results, 364–365
reactions to test results, 368–370
Family history:
adult-onset disorders, 92–93
Alzheimer’s disease genetics, 221
basic principles, 85–88
cancer genetics, 386–391
bilateral breast cancer risk, 393
BRCA mutations and, 387–391
breast conservation and, 391
decision-making guidelines, 391
Index

Family history (Continued)
hereditary/nonhereditary cancer origins, 387
hormone replacement therapy and, 395–396
increased hereditary risk, indications of, 386–387
carrier screening, cystic fibrosis, 259–260
clinical case study, 88
clinical evaluation procedures, 98
common chronic adult disease:
  basic principles, 94
  molecular testing, 97–98
  overview, 93–94
  review procedures and guidelines, 95–97
  risk assessment strategies, 94–95
counseling and educational goals, 98–102
disclosure of test results, legal and ethical issues, 400–402
duty to warn principle, 403–407, 413–414
genetic susceptibility testing, 117
inaccurate/incomplete information risk of, 89–90
management and prevention with, 104–106
maternal serum a-fetoprotein levels, 172
neurogenetics and study of, 223–225
overview of, 85
Parkinson’s disease, 227–228
pedigree analysis, 89
counseling and education using, 99–100
personal history, counseling and education using, 100–101
physical examination, counseling and education using, 101–102
prenatal/neonatal testing, 90–92
practice guidelines, 194–195
reciprocal chromosome translocation case study, 107–108
sampling and laboratory protocols, 292–294
test selection criteria, 102–103
web resources for, 444
Fanconi anemia group C, carrier screening, 265

F508C polymorphism, null allele risk assessment, 348–349
“Fear appeal,” behavior modification using, 50–52
Fetal-derived markers, prenatal screening and diagnosis:
  Down syndrome, 179–181
  trisomy 21 diagnosis, 185–188
Fetal diagnostic testing, communication of results, cultural factors for Latino patients, 31–32
FGFR3 gene, achondroplasia risk assessment, 347–348
First-trimester screening:
  Down syndrome, 182
  trisomy 18, 184
Fluorescence in situ hybridization (HISH), preimplantation genetic diagnosis, 190–192
FMR1 gene, Fragile X syndrome, carrier screening, 266
Follow-up procedures:
  communication of test results, 378–380
  for genetic testing, 30
  prenatal/preimplantation diagnosis, counseling sessions, 215
Forms requirements, for informed consent, 137–138
Founder mutations, breast cancer risk assessment, 349–350
Fragile X syndrome:
  autism and, 221
carrier screening, 266
neurogenetics of, 223
Free choice principle, informed consent and, 133
Fully integrated screening, prenatal diagnosis, 196
GABRB3 genes, autism neurogenetics, 231
GABRG1 and 2 genes, epilepsy neurogenetics, 228–230
Gaucher disease:
carrier screening, 265
newborn screening systems for, 254
G-bandning studies, sampling and laboratory protocols, 292–294
Gender roles, in prenatal testing, 37–40
Gene product assays, carrier screening, 257
Generalized epilepsy with febrile seizures (GEFS+), neurogenetics, 229–238
Genetic clinics, web directory of, 356
Genetic counseling:
- basic principles of, 11–12
- communication of results, 380–382
- core concepts of, 2–3
- cultural considerations in, 15–16
- current trends in, 13–14
- effective strategies for, 16–17
- ethics of, 1, 11–12
- family history and, 98–102
- goals of, 14–15
- historical perspective in, 12–13
- legal aspects of, 82–84
- limitations and applications, 3
- in mainstream medical care, 17–18
- nondirectiveness in, 6–9
- historical perspective on, 12–13
- patient-health care professional relationship, 1–2
- patient motivation and, 3
- physician-patient relationship and, 5–6
- prenatal/preimplantation diagnosis,
  structure of sessions, 215–216
- process vs. outcome in, 7–8
- recent developments in, 1–2
- stress as factor in, 3
- web resources for, 9–11, 356, 445
Genetic determinism:
- innovation in gene research, protection of information and, 434–442
- susceptibility testing and, 288
Genetic discrimination:
- consequences of scientific discovery and, 146–148
- current status, 153–154
- future issues, 154–156
- increases in, 149–151
- insurance coverage:
  - health insurance, 157–160
  - historical background, 156–157
  - life insurance, 160–162
- susceptibility testing and, 287–288
Genetic essentialism, innovation in gene research, protection of information and, 434–442
Genetic exceptionalism, innovation in gene research, protection of information and, 434–442
Genetic reductionism, susceptibility testing and, 288
Genetic screening. See also Prenatal screening and diagnosis
- defined, 18, 20–21
- Genetics model of informed consent,
  131–134
- Genetic susceptibility testing, adult-onset hereditary disorders, 116–117
- Genetic terminology, web resources, 444
- Genetic test centers, referral to, 120
- Genetic testing:
  - applications of, 47
  - archived specimens, 311
  - categories of, 18–22
  - clinical management using, 310–311
  - clinical significance of, 312
  - complexities of interpretation and ordering, 314–317
  - consent to storage vs. consent to test, 311–312
  - defined, 18–19
  - discrimination issues, 146–151
  - genetic counseling approach to, 11–12
  - indications for:
    - burden of disease, 296–297
    - chromosomal anomalies, 297–302
    - molecular and biochemical protocols, 302–307
  - laboratory protocols:
    - obligations, 309–310
    - selection criteria, 319–320
  - limitations of, 312
  - methodologies and utility of, 318–319
  - neurological disorders, limited value of, 222
  - new technologies, 320–321
  - ordering and interpretation:
    - clinician obligations, 307–308
    - submission guidelines, 321
    - patient selection criteria, 317–318
    - physician-patient relationship and:
      - information transfer, 321–322
      - trust as factor in, 3–5
    - posttest guidelines, 327–328
    - process issues, 313–314
Genetic testing (Continued)
results reporting and interpretation, 324–326
sample requirements, 322–323
web resources for, 143–144, 445
Genomic patent policies:
clinical genetic testing services, 335–336
human gene patent debate, 329–331
impact on research and clinical
environment, 333–335
innovation and, 331–333
Myriad Genetics case study, 336–337
overview, 328–329
Gestational age, maternal serum
α-fetoprotein levels, 171–173
GJB2 gene, deafness, carrier screening, 267
Glossary of terms, web resources, 10, 445
Government policies, susceptibility testing, 291
Graphic information, communication of test
results using, 367–368
Harm, risk of:
disclosure of test results and, 400–402
duty of recontacting and, 418–424
legal aspects concerning disclosure of test
results and, 407–408
susceptibility testing, in children and
adolescents, 279–282
HBB gene, hemoglobinopathies, 262–263
H63D gene, hereditary hemochromatosis
susceptibility testing, 271–272
Health care professionals. See also Primary
care physicians
adult-onset disorders, genetic
susceptibility testing, 117
clinicians, genetic testing ordering and
interpretation
obligations, 307–308
communication of results by, 365–370
additional resources for, 378
follow-up and aftercare, 378–379
personal reactions to results, 369
diagnostic genetics and:
accreditation standards, 109–110
competency and referral obligations, 110–111
nonsymptomatic patients, 373–375
obligations, 108–109
prenatal/neonatal diagnosis, obligations
concerning, 111–112
disclosure of test results, duty to warn
principle and obligations
of, 403–407
duty of care standard for, 79–84
family history taking by, 85–88
prenatal/neonatal testing, 90–92
genetic counseling by, 17–18
Huntington disease diagnosis,
communication of results,
373–375
informed consent issues:
background for, 128–130
cultural and socioeconomic factors,
140–141
tone and manner of disclosure,
139–140
interpretation of test results, 363–365
laboratory practices and, 314
nondirected genetic counseling and,
7–8
obligations of, 29
posttest guidelines, 327–328
prenatal screening and diagnosis:
clinical and ethical guidelines,
197–198
nondirectiveness vs. routinization of,
216–217
obligations of, 166
professional disclosure duties, 409–410
duty to warn family members,
413–414
recontact in clinical settings, duties
regarding, 411–413
in research settings, 410–411
recontacting patients, legal, ethical, and
practical issues concerning,
415–424
referral criteria, obligations concerning,
117–120
liability issues, 120–122
resources for, 378
risk assessment, reporting guidelines,
342–343
role in genetic counseling, 2–3
susceptibility testing obligations,
285–286
web resources, 448–449
Index

Health insurance, genetic-based discrimination in, 157–160

Health Insurance Portability and Accountability Act (HIPAA), genetic discrimination and, 153–154

Heart disease risk assessment, low-density lipoprotein (LDL) receptor, 347

Hemoglobinopathies, carrier screening for, 261–263

Hemophilia, prenatal diagnosis, 347–348

Hereditary cancer syndromes, susceptibility testing:
  - breast/ovarian cancer, 273–276
  - signs of increased risk, 386–387
  - colorectal cancer, 276–278
  - familial adenomatous polyposis, 278–279

Hereditary hemochromatosis (HHC): increased risk testing, 358
  - communication of results, 375–376
  - interpretation of results, 325–326
  - susceptibility testing, 270–272

Hereditary hemochromatosis (HHC) diagnostic testing for, 358
  - communication of results, 371–372
  - susceptibility testing, 276–278

Heritability calculation:
  - bipolar disorders, 232–233
  - neurogenetics, 224–225

Hex A deficiency, Tay-Sachs disease, 264–265

HFE gene:
  - hereditary hemochromatosis susceptibility testing, 271–272
  - patent issues, 335–336

High maternal serum chorionic gonadotropin (MS_{CG}), Down syndrome diagnosis, 175–177

Hormone replacement therapy (HRT), breast cancer risk and:
  - family history, 394–395
  - Women’s Health Initiative (WHI) study, 395–397

Human chorionic gonadotropin (HCG):
  - Down syndrome diagnosis, 176–177
  - prenatal screening and diagnosis, 164–165
  - placental-derived markers, 178

Human gene patents:
  - actual vs. potential applications, 433–434
  - ethical debate on, 329–331

Human Genetics Commission of Australia (HGCA), proposal for, 427–429

Human Genome Project (HGP):
  - adult-onset hereditary disorders, 61–62
  - genetic discrimination issues and, 146–151
  - predictive complexity issues, 151–152

Human immunodeficiency virus (HIV), health insurance discrimination, 159–160

Human vision of medical care, prenatal/preimplantation diagnosis and, 214

Huntington disease:
  - genetic testing for, 62–63
  - nonsymptomatic patients, 358, 372–373
  - psychological impact of results, 373–375
  - insurance discrimination and, 161–162
  - interpretation of results, 325–326
  - neurogenetics of, 223
  - psychological aspects of genetic counseling and testing for, 54
  - risk assessment for, 345–346

Hyperechoic bowel, trisomy 21 diagnosis, 186

Idioms and jargon:
  - communication of test results and, 33–34
  - in consent forms, 137–138

Idiopathic generalized epilepsies (IGEs), neurogenetics, 228–230

Inaccurate/incomplete information, in family history, 89–90

Inborn errors of metabolism, newborn screening, 239–243

Cost effectiveness of, 248–250

Tandem mass spectrometry, 250–252
Index

Inclusion criteria, newborn screening systems, 253–254
Increased risk:
  defined, 362
  testing for, communication of results, 375–376
Indications for testing:
  burden of disease standard, 296–297
  changes in standards for, 313
  chromosomal anomalies, 297–302
  molecular and biochemical protocols, 302–307
Information-only services, duty of recontacting and use of, 423–424
Information transfer:
  communication in genetic testing and counseling and, 24–25
  communication of test results, 355–356, 366–368
  current regulatory framework, 426–427
  decision-making and role of, 50–52
  disclosure of test results, duty to warn principle, 403–407
  genetic innovation and:
    actual vs. potential applications, 433–434
    human interest in, 429
    policy action plan for, 434–442
    public ambivalence concerning, 429–431
    rapid changes in, 431–432
  medical genetics, key recommendations, 427–429
  prenatal diagnosis, informed consent procedures, 209–211
  genetic conditions information, 211–212
  protection of genetic innovation and:
    actual vs. potential applications, 433–434
    current regulatory framework, 426–427
    human interest in, 429
    objectives, 425–426
    policy action plan for, 434–442
    public ambivalence concerning, 429–431
    rapid changes in, 431–432
  Informed choice principle, 133
Informed consent:
  communication issues, 136–137
  cultural and socioeconomic differences, 140–141
  current legal status of, 153–154
  delegation of duties regarding, 140
  disclosure issues, 132–134
  discussion time and place issues, 138–139
  doctrine of, 128–130
  educational tools for, 142–143
  forms for, 137–138
  future issues, 154–156
  genetic discrimination consequences:
    anticipation of, 146–148
    impact of Human Genome Project on, 149–151
    insurance coverage, 156–162
    genetics model of, 131–134
    health care professionals’ tone and manner, 139–140
    legal models of, 130–131
    linguistic differences, 141–142
    newborn screening, 246–247
    overview of, 128
    predictive complexity of genetic conditions, 151–152
    preimplantation genetic diagnosis, 216
    prenatal genetic diagnosis, 206–208
    abnormal results, options available with, 212
    emotional and psychosocial counseling, 214
    genetic conditions information, 211–212
    information about procedures, 210–212
    pre- and posttest counseling, 214–216
    social pressures for decision, 213–214
    stigma of disability and, 213
    for specimen storage vs. testing, 311–312
    test validity and utility, 134–135
    web resources for, 143–145
Innovation in gene research:
  patent issues and, 331–333
  protection of information and:
    actual vs. potential applications, 433–434
    current regulatory framework, 426–427
human interest in, 429
policy action plan for, 434–442
public ambivalence concerning, 429–431
rapid changes in, 431–432
technical advances, 320–321
Insulin-dependent diabetes mellitus (IDDM), maternal serum α-fetoprotein levels, 172
Insurance issues:
  genetic discrimination and, 146–151
  health insurance, 157–160
  historical background, 156–157
  life insurance, 160–162
web resources for, 143, 446
Integrated biochemistry-only screening, trisomy 18, 184
Integrated first- and second-trimester screening, Down syndrome diagnosis, 182–183
Intellectual characteristics, of genetic testing client, 48
Interleukin-1β gene, epilepsy neurogenetics, 228–230
International laboratory practices, 314
Interpretation complexity in test results, 324–326
Invasive lobular carcinoma, risk assessment, 394
In vitro fertilization (IVF), preimplantation genetic diagnosis, informed consent and, 216
Jargon:
  communication of test results and use of, 33–34
  in consent forms, 137–138
  Joint probability, in risk assessment, 344–345
Karyotyping techniques:
  chromosome anomalies, adult-onset disorders, 302
  sampling and laboratory protocols, 292–296
  KCNJ10 gene, epilepsy neurogenetics, 229
  KCNQ2 and 3 gene, epilepsy neurogenetics, 229–230
  Laboratories:
  accreditation, quality assurance, and quality management protocols, 309–310
  genetic testing protocols, 294–296
  clinician obligations regarding, 307–308
  legal obligations of, 309–310
  interpretation of test results, duties regarding, 363–365
  limitations of testing, 352–353
  ordering and interpretation complexities, 314–319, 321
  performance obligations in genetic testing, 309–310
  process issues in, 313–314
  quality systems, 327
  reporting responsibilities of, 309
  requisitions requirements, 313
  sample requirements of, 322–323
  selection criteria for, 319–320
  web resources for, 144, 446
Language issues in genetic testing, 336–338.
  See also Idioms and jargon;
  Multilingualism
  genetic testing and role of, 37–40
  case history of, 37–38
  family and friends as translators, 39–40
  on-site translators, 37
  post-consultation interview, 38–39
  informed consent issues and, 38–39
  web resources for, 144, 446
Late-onset conditions:
  Alzheimer’s disease genetics, 221
  prenatal and preimplantation diagnosis, 200–201
  lateral ptemporal-lobe epilepsy, neurogenetics, 229–230
  Latino patients, fetal diagnosis
    communication, cultural factors, 31–32, 36–37
  Legal aspects of genetics testing, See also
  Ethics of genetics testing and counseling; Liability; Tort actions
  abortion laws and, 204–206
  adult-onset disorders, genetic susceptibility testing, 117
582  Index

Legal aspects of genetics testing (Continued)
clinician clinicians ordering and
interpretation obligations, 307–308
confidentiality issues, 398–400
diagnostic genetics:
  competency and referral, professional
  obligations regarding, 110–111
  prenatal/neonatal diagnosis, 111–112
  wrongful abortion claims, 116–117
  wrongful adoption claims, 126–127
  wrongful birth claims, 112–114
  wrongful life claims, 112, 115–116
disclosure of test results, 400–402
  duty to warn principle, 403–407
  professional disclosure duties, 409–410
  duty to warn family members, 413–414
  recontact in clinical settings, duties
  regarding, 411–413
  in research settings, 410–411
  risks and harm, issues of, 407–408
  web resources on, 408
duty of care standard, 79–84
duty to warn obligations, 403–404
family history taking, 86–87
  inaccurate/incomplete information,
  89–90
  prenatal/neonatal testing, 91–92
  genetic discrimination issues, 146–151
  current status, 153–154
  genetic innovation and protection of
  information, 426–427
  genomic patent policies:
    clinical genetic testing services,
    335–336
    human gene patent debate, 329–331
    impact on research and clinical
    environment, 333–335
    innovation and, 331–333
    Myriad Genetics case study, 336–337
    overview, 328–329
informed consent:
  background for, 128–130
  models for, 130–131
  web resources for, 144
laboratory performance
  obligations, 309–310
laboratory requisitions requirements, 313
newborn screening, 240, 246–247
physician-patient relationship and, 81–84
physician standard of care, 80–81
predictive complexity and, 151–152
prenatal screening and diagnosis, 189–196
abortion laws, 204–206
access problems, 193–194
confidentiality, 217–218
disability screening, 201–204
ethnicity-based practice guidelines, 194
family history and, 194–195
health care provider obligations, 197–198
maternal age, 195
medical factors, 196
pregnancy history, 195
prenatal/neonatal diagnosis, 217–218
public policy, 198
sex selection, 198–200
standards of usefulness, 139–194
ultrasound examination and
  biochemical markers, 196
recontacting patients, issues involving,
  415–424
web resources, 446
Legislation on genetics:
  newborn screening programs, 246–24
web resources for, 143, 446
LGH gene, epilepsy neurogenetics, 230
Liability. See also Tort actions
  adult-onset disorders, genetic
    susceptibility testing, 117
diagnostic genetics:
  competency and referral, professional
  obligations regarding, 110–111
  wrongful birth claims, prenatal/neonatal
    diagnostic testing, 112–114
disclosure of test results, duty to warn
  principle, 403–407
family history taking and issue of, 87–88
in genetic counseling, 82–84
of primary care physicians, referral
  obligations, 121–122
wrongful abortion claims, 116
wrongful life claims, prenatal/neonatal
  diagnosis, 112, 115–116
Life insurance, genetic discrimination and, 160–162
Linkage analysis:
disease diagnosis, 305
neurogenetics, 224–225
risk assessment with, 350–352
sample requirements, 323
schizophrenia neurogenetics, 232
Low-density lipoprotein (LDL) receptor, heart disease risk assessment, 347
Lysosomal storage disease:
biochemical testing for, 306–307
newborn screening systems for, 254
Mainstream medicine, role of genetic counseling in, 17–18
Malpractice law:
diagnostic genetics and, prenatal/neonatal diagnosis, 112
disclosure of test results, duty to warn principle, 403–407
Management and prevention of chronic disease, family history as tool for, 104–105
MAOA gene, conduct disorder, 233–235
Maternal age:
genetic counseling and, family history and, 88
prenatal and preimplantation diagnosis, 195
second-trimester Down syndrome screening, 181–182
Maternal serum α-fetoprotein (MSAFP):
Down syndrome diagnosis, 175–177
prenatal screening and diagnosis, 171–173
second-trimester Down syndrome screening, 181–182
trisomy 18, 183–184
Maternal serum screening, prenatal diagnosis, 196
Maternal weight, maternal serum α-fetoprotein levels, 171–173
MCAD deficiency, newborn screening for, 240, 243
cost effectiveness of, 249–250
Mean Corpuscular Volume (MCV), hemoglobinopathy screening, 262–263
Media coverage, of genetic discrimination issues, 149–151
Medical devices, risks of, duty to warn patients concerning, 423
Medical information bureau (MIB), health insurance discrimination, 160
Medical vision of care:
laboratory requisitions, 313
prenatal/preimplantation diagnosis and, 214
Mendelian inheritance, autism, 221
Mental illness, wrongful adoption claims and, 126–127
3-Methylcrotonyl-CoA carboxylase deficiency, newborn screening for, 249–250
Microdeletions/microduplications, cytogenetic studies, 301
Microtubule-associated protein τ (MAPT) gene, Parkinson’s disease, 227–228
Misinterpretation of test results:
genetic counseling and issues of, 42–44
by physicians, 27
prenatal genetic care and, 32–37
psychological aspects of genetic counseling and testing and, 54–55
MLH1 and 2 genes, hereditary nonpolyposis colon cancer, susceptibility testing, 276–278
symptomatic patient case study, 371–372
Molecular genetics testing:
chronic adult disease, family history and, 97–98
clinical diagnosis, neurofibromatosis case study, 46
disease diagnosis, 302–307
indications for, 296
limitations of, 312
risk assessment, 340–341
sampling and laboratory protocols, 295–296
schizophrenia, 231–232
Monitoring, as coping mechanism, communication of test results and, 368–369
MPTP neurotoxin, Parkinson’s disease, 226–228
Index

**MSH2** gene, hereditary nonpolyposis colon cancer, susceptibility testing, 276–278

**MSH6** gene, hereditary nonpolyposis colon cancer, susceptibility testing, 276–278

Mucolipidosis, carrier screening, 265

Multilingualism:
- genetic testing and role of, 37–40
  - case history of, 37–38
  - family and friends as translators, 39–40
  - on-site translators, 37
  - post-consultation interview, 38–39
  - informed consent issues and, 141–142

Multiple gene testing, 289–290

Multiple gestation pregnancies, maternal serum α-fetoprotein levels, 172

Multiple significance testing, breast cancer risk and hormone replacement therapy, 395–397

Mutation nomenclature, risk assessment and, 353–354

**MYH** gene, familial adenomatous polyposis, 279

Myriad Genetics, patents owned by, 336–337

Nasal bone abnormalities, trisomy 21 diagnosis, 188

Need to know principle, communication in genetic testing and counseling and, 27–28

Negative predictive value, newborn screening tests, 247–248

Negative test results:
- accuracy of, for risk assessment, 343–344
  in adult-onset hereditary disorders testing (absence of mutation), psychological impact of, 70–71
  complexity in interpretation, 324–326

Negligence claims:
- family history taking and issue of, 87–88
  prenatal/neonatal diagnostic testing:
  - tort elements, 124–125
  - wrongful birth claims, 112–114

Neural tube defects, prenatal screening and diagnosis, 169–170

Neuregulin 1 gene, schizophrenia, 232

Neurofibromatosis case study, clinical diagnosis:
- diagnostic criteria, 45
- molecular genetics, 46
- patient history, 44–45

Neurogenetics:
- overview of, 223
  research methodology, 223–225

Neuroligin genes, autism neurogenetics, 231

Neurological disorders:
- Alzheimer’s disease:
  - clinical presentation, 220–221
  - neurogenetics, 225–226
- autism:
  - classification, 221
  - genetics of, 230–231
- bipolar disorders:
  - classification, 222
  - genetics of, 232–233
- clinical presentation, 220
- conduct disorder, genetics of, 233–234
- epilepsies:
  - classification, 222
  - genetics of, 228–230
- genetic testing, ethical and legal issues, 234–236
- limitations of testing, 222

Neurogenetics research, 223–225

Parkinson’s disease:
- clinical presentation, 221
- neurogenetics, 226–228
- research overview, 219–220

schizophrenia:
- classification, 222
- genetics of, 231–232

Newborn diagnosis and screening. See also Children

applications, 238–239
basic principles, 241–242
competency and referral, professional obligations regarding, 111–112
core concepts, 239–241
current status, 252
cytogenetics, 300–301
educational tools, 253
family history and, 90–92
future issues, 253–254
historical background, 242
586  Index

Patient comprehension:
  communication in genetic testing and
counseling and, 24–28
  obligations concerning, 29
  risk communication and, 359–363
  of test results, 363–365
Patient education, web resources, 356, 449
Patient expectations, genetic counseling
  and, 16–17
Patient history:
  adult-onset hereditary disorders testing,
  assessment in pretest phase, 64–66
  communication of results, psychological
  aspects, 373–374
  cystic fibrosis carrier testing, 377–378
  family history derived from, 85–87
  genetic counseling and education using,
  100–101
  genetic diagnosis, nonsymptomatic
  patients, 373–375
  increased risk testing, 375–376
Patient motivation:
  adult-onset hereditary disorders testing,
  pretest phase of, 63–66
  genetic counseling and role of, 3
Patient obligations, duty of recontacting and
  role of, 419–420
Patient registry, referrals for diagnostic
testing and, 121–122
Patient selection criteria, for genetic
testing, 317–319
Pedigree analysis:
  family history and, 89
  genetic counseling and education
  using, 99–100
  as genetic counseling educational tool,
  49–50
  risk assessment, 344–345
Perceived risk:
  adult-onset hereditary disorders testing, in
  pretest phase, 64–66
  psychological aspects of genetic
counseling and testing and, 57
Perception, psychological aspects of genetic
counseling and testing and, factors
  affecting, 59–60
Phenylketonuria (PKU), newborn
  screening, 241–243
  cost effectiveness of, 248–250
  legal aspects of, 246–247
Physical examination, genetic counseling and
  education using, 101–102
Physician-patient relationship. See also
  Health care professionals; Primary
  care physicians
  communication in genetic testing and
counseling:
    client cultural and intellectual
    characteristics, 48
    clinical diagnosis case study, 44–47
    confidence and trust issues, 40–42
    amniocentesis, women’s acceptance
    of, 41–42
    amniocentesis, women’s refusal
    of, 40–41
    decision-making considerations and
    approaches, 50–52
    diagnostic criteria and, 45
    educational tools and facilitators,
    48–50
    effectiveness of, guidelines for, 24–27
    ethical issues, 46
    counseling guidelines, 46–49
    fetal diagnosis, cultural factors in,
    considerations for Latino
    patients, 31–32
    informed consent and, 136–137
    methods for, 30
    miscommunication and patient
    dissatisfaction, 42–44
    molecular genetics principles, 46
    multilingualism, translation and
    second-hand information issues,
    37–40
    family and friends as translators,
    39–40
    genetic consultation, 37–38
    on-site translators, 37
    post-consultation interview, 38–39
    need to know principle, 27–28
    patient history, 44–45
    physician-patient relationship and,
    24–25
    prenatal genetic care,
    miscommunication and, 32–37
    cultural sensitivity, 35
    genetic consultation, 35–36
idioms and jargon, 33–34
nondirectiveness, guidelines for, 34–35
opportunistic observation, 36–37
professional obligations in, 29
standards for, 28–29
terminology, tone, and follow-up guidelines, 30
test results, steps for communication of, 365–370
duty of care principles, 81–84
evolution of, 3–5
 genetic counseling and, 5–6
 goal identification, 14–15
 nondirectiveness in, 6–9
 genetic testing and, trust as factor in, 3–5
 laboratory reports communicated with, 321–322
 recontacting patients:
 in clinical settings duties regarding, 411–413
 ethical, legal, and practical concerns, 415–424
PINK1 gene, Parkinson’s disease, 227–228
Placental-derived markers, prenatal screening and diagnosis, 178–179
Policy issues:
genetic discrimination an, 154–156
innovation in gene research, protection of information and, 434–442
newborn screening, 244–245
prenatal genetic diagnosis, 166–167
ethics and legal aspects, 198
web resources for, 145, 446, 450
Polymerase chain reaction (PCR):
limitations of, 352
preimplantation genetic diagnosis, 190–192
Population data, genetic test results and, 360–361
Positive predictive value, newborn screening tests, 247–248
Positive test results:
accuracy of, for risk assessment, 343–344
in adult-onset hereditary disorders testing (presence of mutation),
psychological impact of, 69–70
complexity in interpretation, 324–326
newborn screening, 244
in prenatal diagnosis, informed consent options, 212
Posterior probability, in risk assessment, 344–345
Posttest counseling:
communication of test results, managing aftermath of, 369–370
complexities in, 327–328
prenatal/preimplantation diagnosis, 214–215
Prader Willi-Angelman syndrome, 221
Preconception carrier screening, strategies for, 258
Predictive complexity:
and genetic conditions, 151–152
suscettibility testing, risk prediction vs. diagnosis, 287
Predictive genetic testing, defined, 21
Pregnancy-associated plasma protein A (PAPP-A):
Down syndrome diagnosis, 176–177
prenatal screening and diagnosis, 164–165
mechanisms of, 179
trisomy 18, 184
Pregnancy history, prenatal and preimplantation diagnosis, 195
Preimplantation genetic diagnosis (PGD):
evidence-based access, 193–194
informed consent and, 216
legal and ethical issues, 189–196
abortion laws, 204–206
access problems, 193–194
confidentiality, 217–218
ethnicity-based practice guidelines, 194
family history and, 194–195
health care provider obligations, 197–198
maternal age, 195
medical factors, 196
pregnancy history, 195
public policy, 198
sex selection, 198–200
standards of usefulness, 139–194
ultrasound examination and biochemical markers, 196
overview of, 190
prenatal screening, 166
Index

Preimplantation genetic diagnosis (PGD)
(Continued)
sex selection, 198–200
susceptibility testing, 200–201
techniques for, 190, 192–193
Prenatal diagnosis (PND). See also Children;
Newborn diagnosis and screening
access issues, 166
achondroplasia risk assessment, 348
basic concepts, 167–170
basic principles, 20
case study, 167–170
communication of results:
cultural factors for Latino patients, 31–32
idioms and jargon used in, 33–34
miscommunication of, 32–37, 42–44
competency and referral, professional obligations regarding, 111–112
congenital anomalies, 299–300
core concepts, 164
disability-based selection, 201–204
Down syndrome, 175–177
contingent sequential screening, 183
first-trimester screening, 182
integrated first- and second-trimester screening, 182–183
second-trimester screening, 181–182
family history and, 90–92
fetal-derived markers, 179–181
goals of, 163–164
health care provider obligations, 166
informed consent and genetic counseling, 206–214
abnormal result, available options for, 212
barriers to, 208–209
characteristics of conditions, 211–212
emotional and psychosocial counseling, 214
follow-up counseling, 215
nondirectiveness issues, 216–217
pre- and posttest counseling, 214–216
procedure information, 209–211
social aspects of disability, 213
social pressures on decision-making, 213–214
structuring of counseling session, 215–216
legal and ethical issues, 189–196
abortion laws, 204–206
access problems, 193–194
confidentiality, 217–218
ethnicity-based practice guidelines, 194
family history and, 194–195
health care provider obligations, 197–198
maternal age, 195
medical factors, 196
pregnancy history, 195
public policy, 198
sex selection, 198–200
standards of usefulness, 139–194
ultrasound examination and biochemical markers, 196
limitations of, 210–211
neural tube defects, 169–170
overview, 163
placental-derived markers, 178–179
preimplantation diagnosis, 166
recent techniques, 164–165
reciprocal chromosome translocation case study, 107–108
referral criteria, 118–119
routinization of, 216–217
screening vs. diagnosis issues, 210–211
societal issues and public policies, 166–167
summary of developments, 188–189
susceptibility testing and late-onset conditions, 200–201
trisomy 18, 183–188
first-trimester screening, 184
integrated biochemistry-only screening, 184
second-trimester screening, 183–184
trisomy 21:
echogenic intracardiac focus, 187
hyperechoic bowel, 186
increased nuchal fold, 185–186
nasal bone abnormalities, 188
renal pyelectasis, 187
second-trimester ultrasound markers, 185–188
shortened limbs, 186
web resources for, 447–448
wrongful abortion claims, 116
wrongful birth claims, 112–114
wrongful life claims, 112, 115–116
Presenilin 1 and 2 genes, Alzheimer’s
disease genetics, 221, 225–226
Presymptomatic testing, defined, 21
Pre-test counseling:
prenatal/preimplantation diagnosis, 214–215
test results, impact on, 357
Pretest phase, genetics diagnosis:
adult-onset hereditary disorders testing,
psychological aspects, 63–66
impact on successful test results of, 357
Prevention techniques for chronic disease:
disclosure of test results and, 400–402
family history as tool for, 104–105
Primary care physicians. See also Health
care professionals;
Physician-patient relationship
referral obligations of, 120–122
Primum non nocere principle, genetic testing
and, 1, 4
Prior probability, in risk assessment,
344–345
Privacy issues, genetic innovation and
protection of information and,
430–431
Private investment, gene patent
innovation, 331–333
Professional organizations, web resources,
448–449
Prognosis, breast and ovarian cancer,
diagnosis vs., 385–386
Protease inhibitor gene, alpha-1-antitrypsin
(AAT) deficiency, susceptibility
testing, 272
Proteomics, genetic innovation and
protection of information and, 432
Psychological aspects of genetic counseling
and testing:
adult-onset hereditary disorders, 61–78
ambiguous test results, guidelines for,
71–72
clinical implications of, 74–77
disclosure of result, posttest phase,
66–67
family reactions to, 72–73
negative test result, absence of
mutation, 70–71
positive test result for mutation, 67–70
pretest counseling phase, 63–66
societal and ethical issues, 73–74
testing process, 62–63
anxiety and perceived risk, patient’s
pretest status, 57
basic principles, 53–54
chromosomal translocation case study,
54–55
communication of test results:
case studies in, 371–375
clinical limitations of, 373
followup and aftercare
procedures, 379–380
health care professionals’ reaction,
369
impact of results, 369–370
language issues, 366–368
nonsymptomatic patient, diagnostic
testing in, 372–373
patient/family reactions, 368–369
patient history and
characteristics, 373–375
setting for, 366
symptomatic patient, diagnostic testing
in, 371–372
timing, 365
Huntington disease case study, 54
increased risk testing, impact of results,
375–376
informed consent, web resources for, 144
perception factors, 59–60
potential for benefit, 56–57
potential for harm, 56
prenatal/preimplantation diagnosis,
emotional and psychosocial
counseling, 214
research background, 53
standards and interpretation, 60–61
stress as factor in, 57–58
stress management, 58–59
web resources for, 449
Public health:
genetic discrimination issues in, 154–156
newborn screening policies, 244–245
susceptibility testing, 291
web resources for, 145, 449–450
Purine metabolism disorders, biochemical
testing, 306–307
590  Index

Quad screen protocol, prenatal screening and diagnosis, 196
Quality assurance/quality management protocols:
  laboratory accreditation, 309–310
  systems in laboratories for, 327
Quality of life benefits, adult-onset hereditary disorders testing, positive results (presence of mutation), response to, 70
Racial origin, maternal serum α-fetoprotein levels, 171–173
Reciprocal chromosome translocation:
  family history of, 88
  prenatal diagnosis, spina bifida case study, 107
  psychological aspects of genetic counseling and testing for, 54–55
Recontacting patients:
  in clinical settings duties regarding, 411–413
  ethical, legal, and practical concerns, 415–424
  methods for, 420–421
Recurrence risk, defined, 362
Referral, in diagnostic genetics:
  criteria for, 117–120
  primary care physicians, obligations of, 120–122
  professional obligations regarding, 110–111
Regulatory framework, genetic innovation and protection of information, 426–427
Relative risk, defined, 361
Renal pyelectasis, trisomy 21 diagnosis, 187
Repeat testing, indications for, 313–314
Reporting requirements for test results:
  interpretation complexity, 324–326
  written results, 363
  of laboratories, 309
  risk assessment guidelines, 342–343
Reproductive decision making:
  genetic counseling and:
    current trends in, 14
    historical perspective, 12–13
  prenatal genetic diagnosis:
    abortion laws, 204–206
    informed consent issues, 207–208
Research environment in genetics:
  communication of results in, 410–411
  impact of patents in, 333–335
  web resources, 445
Results of tests. See Test results
Retinoblastoma, prenatal testing for, 347–348
“Right not to know” principle, prenatal diagnosis, informed consent procedures, 211–212
Risk assessment:
  adult-onset hereditary disorders, benefits of, 61–62
  breast cancer:
    average population risk, 384–385
    bilateral risk, 392–394
    family history and, 386–391
    founder mutations, 349–350
    hormone replacement therapy and, 394–397
    calculation of, techniques for, 344–345
  common chronic adult disease:
    family history, 95–97
    for individuals, 94–95
    communication of:
      language skills for, 366–368
      legal aspects concerning, 407–408
      resources for, 356
      setting for, 366
      timing of, 365
    cystic fibrosis, 346–347
    definition of, 361–362
    disclosure of test results, duty to warn principle, 403–407
    FGFR3, achondroplasia, and thanatophoric dwarfism, 347–348
  health care professionals’ duties regarding, 342–343
  Huntington disease, 345–346
  laboratory testing, 340
  limitations of, 352–353
  LDL receptor heart disease risk, 347
  limitations of testing, 341–342
  linkage analysis and Alport syndrome, 350–352
  molecular testing, 340–341
mutation nomenclature, 353–354
negative test results, accuracy of, 343
null alleles, 348–349
overview, 340
patient understanding of, 16–17
positive test results, accuracy of, 343–344
predictive accuracy of results, 343
susceptibility testing:
  benefits vs., 269–270
  identification and understanding of, 286
  prediction vs. diagnosis, 287
web resources for, 145, 450
Roe v. Wade, 204–205
Sample collection protocols:
  basic requirements, 322–323
  case studies, 292–294
  laboratory requirements, 322–323
  overview of, 292
Schizophrenia:
  clinical presentation, 222
  neurogenetics, 231–232
Screen negative risk, prenatal screening and diagnosis, 168–170
Screen positive risk, prenatal screening and diagnosis, 167–170
Second-trimester screening:
  Down syndrome, 181–182
  trisomy 18, 183–184
  trisomy 21, 185–188
  “Selective mentality” of prenatal testing, stigmatization of disability and, 202–203
Sensitivity:
  newborn screening tests, 247–248
  of test results, 359
Sex selection, prenatal genetic diagnosis, ethical issues, 198–200, 203
Shortened limbs, trisomy 21 diagnosis, 186
Sickle cell disease:
  carrier screening, 261–263
  insurance discrimination and, 162
  susceptibility testing, 289
Sickle cell trait, 162
  susceptibility testing, 289
Simultaneous multiple gene testing, 289–290
Single-gene disorders, newborn screening systems for, 254
Smith-Lemli-Opitz syndrome, amniocentesis sampling and laboratory protocols, 294
Societal issues:
  prenatal genetic diagnosis, 166–167
  prenatal/preimplantation genetic diagnosis:
    pressures for decision making, 213–214
    stigmatization of disability, 213
    psychological aspects of genetic testing, 73–74
Socioeconomic issues, informed consent and, 140–141
Somatic mutations, sampling and laboratory protocols, 295–296
Specificity:
  newborn screening tests, 247–248
  of test results, 359
Specimen requirements, for genetic testing, 322–323
  limitations of testing with, 352–353
Standards:
  in diagnostic genetics, 109–110
  for genetic counseling, 28–29
  for informed consent, legal models for, 130–131
  obsolescence in, 313–314
  of patient care, 80–81
  tort claims and, 124–125
  psychological aspects of genetic counseling and testing and, 60–61
Stigma of disability, prenatal/preimplantation genetic diagnosis:
  ethical aspects, 202–203
  social aspects of, 213
Storage of specimens, for genetic testing, informed consent for, 311–312
Stress:
  in adult-onset hereditary disorders testing:
    disclosure of results, counseling guidelines, 66–67
    negative results (absence of mutation), 70–71
    positive results (presence of mutation), levels of, 67–70
    during pretest phase, 66
Stress (Continued)
communication of results as trigger for, 369–370
genetic counseling and role of, 3
psychological aspects of genetic counseling and testing and:
clinical implications, 74–77
coping strategies for, 58–59
potential for harm from, 56
recognition of, 57–58
Summary letters, as genetic educational tool, 49–50
Support groups, web resources, 357, 450–451
Susceptibility testing:
alpha-1-antitrypsin deficiency, 272
benefits and risks, 269–270
in children, 279–282
benefits of, 280–281
decision making principles, 282
ethical issues, 279–280
potential harm, 281
risk-benefit tradeoff, 288–289
defined, 21
direct to consumer testing, 290–291
disease vs. traits, testing for, 289
ethical issues, 287
genetic determination, 288
genetic discrimination based on,
287–288
genetic reductionism, 288
genetic testing:
case study, 282–283
risk-benefit analysis, 283–285
goals and applications, 268–269
government role in, 291
health care planning, 285
hereditary cancer syndromes:
breast/ovarian cancer, 273–276
colorectal cancer, 276–278
familial adenomatous polyposis, 278–279
hereditary hemochromatosis, 270–272
neurogenetic testing, 235–236
overview of, 268
preimplantation genetic diagnosis, ethical issues, 200–201
resources for, 285–286
risk prediction vs. diagnosis, 287
risks of, 286
simultaneous multiple genetic testing,
289–290
Symptomatic patients, diagnostic testing,
hereditary nonpolyposis colon cancer, 371–372
Systems approach, newborn screening programs, 245
Talent identifications, actual vs. potential applications of genetic information and, 433–434
Tamoxifen, breast cancer prevention and, 391–392
bilateral breast cancer risk, 392–393
Tandem mass spectrometry (TMS):
disease diagnosis, 304–307
newborn screening, 240, 250–252
cost effectiveness of, 248–250
cost issues, 241
current status, 252
MCAD deficiency, 242–243
PKU screening, 242–243
Target populations, carrier screening, 256–257
Tay-Sachs disease, carrier screening, 255
Ashkenazi Jewish population, 263–265
case study, 255–256
protocols for, 256–258
Technical advances, in genetics testing, 320–321
genetic innovation and protection of information and, 431–432
Terminology, in genetic testing, 30
Test characteristics:
methodology of testing, 360
newborn screening, 247–248
Test results:
in adult-onset hereditary disorders testing:
ambiguous results, 71–72
negative results (absence of mutation), 70–71
positive results (presence of mutation), 67–70
clinical management applications, 310–311
communication of:
language used in, 366–368
patient comprehension, 359–363
Index 593

risk information, 363–365
setting for, 366
timing of communication, 365
disclosure issues with, 400–402
impact of pretest procedures on, 357
interpretation of, 363–365
laboratory reporting responsibilities, 309
miscommunication of, 25
newborn screening, positive results, confirmation of, 244
overview of, 355–356
patient comprehension of, 27–28
reporting and interpretation, 324–326
resources for, 378
validity and utility, informed consent and, 134–135
web resources for, 356
Test selection criteria, family history and genetic screening, 102–103
Thalassemias, carrier screening for, 256–257, 261–263
Thanatophoric dysplasia, risk assessment for, 348
Therapeutic model of care, genetic testing and, 4
Third party protection, recontacting patients and duty of, 422–423
Threshold values:
duty of recontacting and, 419
newborn screening, 239–240
Tone of communication, in genetic testing, 30
Tort actions, diagnostic genetics testing, 123–127
elements of tort claims, 124–125
wrongful adoption, 126–127
wrongful birth, 123–124
wrongful life, 125–126
Traditional medicine, genetic medicine vs., 17–18
“Tragedy of anticommons” in gene patenting, 333–335
Traits, susceptibility testing for, 289
Translators:
educational activities of, 49–50
genetic testing and role of, 37–40
family and friends as, 39–40
on-site translators, 37–38

“Triple screen” protocol:
Down syndrome diagnosis, 176–177
prenatal screening and diagnosis, 164–165
maternal serum screening, 196
Trisomy 18:
prenatal screening and diagnosis, 183–188
first-trimester screening, 184
integrated biochemistry-only screening, 184
second-trimester screening, 183–184
triple or quad screen test, 196
Trisomy 21, prenatal screening and diagnosis:
echogenic intracardiac focus, 187
hyperechoic bowel, 186
increased nuchal fold, 185–186
nasal bone abnormalities, 188
renal pyelectasis, 187
second-trimester ultrasound markers, 185–188
shortened limbs, 186
Trust:
in communication of genetic test results, 40–42
in physician-patient relationship, genetic testing and, 3–5
Twin studies:
epilepsy, 228–230
neurogenetics, 223–225
schizophrenia, 231–232
Ubiquitin C-terminalhydrolase L1 (UCHL1) gene, Parkinson’s disease, 227–228
Ultrasound examination:
open neural tube defects, 173–175
prenatal diagnosis and screening, 196
“routinization” of, 210–211
trisomy 21 diagnosis, 185–188
Unconjugated estriol (MSuE3):
Down syndrome diagnosis, 176–177
mechanisms of, 179
United States abortion laws, 204–205
Utility of testing, informed consent and, 134–135
Index

Validity of testing, informed consent and, 134–135
Values and beliefs, communication in genetic testing and counseling and impact of, 26–27
Videos:
as genetic counseling educational tool, 49–50
informed consent and use of, 142–143
Web resources:
availability of genetic testing, 317
cancer genetics, 443
confidentiality and disclosure of test results, 408
continuing education, 443–444
continuing medical education, genetics, 9
for diagnostic genetics, 110
ethics of genetics testing and counseling, 444
family history, 444
genetic counseling organizations, 9–11, 356, 445
genetic research, 445
genetics clinic directory, 356
genetic terminology, 444
genetic testing, 143–144, 445
glossary of terms, 10, 445
for informed consent, 143–145
insurance in, 446
laboratories for genetic testing, 10, 446
for languages, 446
law and legislation on genetics, 143, 446
patient education and risk communication, 356, 449
policy issues, 145, 446, 450
prenatal/neonatal testing, 447–448
professional organizations, 448–449
professional organizations on, 10–11
psychological aspects of genetics, 449
public health, 145, 449–450
referral criteria, 118
risk communication, 145, 450
support groups, 357, 450–451
Women’s Health Initiative (WHI) study, breast cancer risk and hormone replacement therapy, 395–397
Wrongful abortion claims, prenatal genetic diagnosis, 116
Wrongful adoption claims, diagnostic genetics and, 126–127
Wrongful birth claims, diagnostic genetics and:
prenatal genetic diagnosis, 112–114
tort actions, 123–124
Wrongful life claims, diagnostic genetics and:
prenatal genetic diagnosis, 112, 115–116
tort claims, 125–126
X-linked recessive pedigree, risk assessment, 344–345